nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We need to tidy up around the castle, catch up on our napping, and plan to spend time with our short person. We may also promenade with the mascots. And what about you? Perhaps this is a good time to plan a spring break, reach out to someone special, or donate to the arts, which may need some help. Or you could check to see if you were wiretapped recently. But please do remember to gather evidence. Well, whatever you do, have a grand time, but be safe. Enjoy, and see you soon …

AstraZeneca was dealt another setback by the Food and Drug Administration in its quest to win approval for a drug that treats hyperkalemia, a condition in which potassium levels in the blood are too high, the Financial Times says. The FDA issued a complete response letter, meaning the drug will not be approved. This is the second time the FDA declined to approve the drug, which AstraZeneca acquired when it bought ZS Pharma for $2.7 billion in 2015.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy